Loading...
•
Dec 31, 2024
Puma Biotechnology Q4 2024 Earnings Report
Puma Biotechnology reported its financial results for the fourth quarter and full year ended December 31, 2024, showing an increase in net income and product revenue for the quarter.
Key Takeaways
Puma Biotechnology announced strong financial results for the fourth quarter of 2024, with net income increasing to $19.3 million and product revenue reaching $54.4 million. The company also reported positive net income for the third consecutive year, driven by commercial performance and strategic initiatives.
Product revenue, net, for Q4 2024 was $54.4 million, an increase from $53.2 million in Q4 2023.
Net income for Q4 2024 was $19.3 million, or $0.39 per basic and diluted share, up from $12.3 million in Q4 2023.
Non-GAAP adjusted net income for Q4 2024 was $21.1 million, or $0.43 per basic and diluted share.
Net cash provided by operating activities for Q4 2024 was $15.6 million, compared to $10.5 million in Q4 2023.
Revenue by Segment
Forward Guidance
Puma Biotechnology provided financial outlook for the first quarter and full year 2025, anticipating continued revenue generation and positive net income.
Positive Outlook
- Anticipated net product revenue for Q1 2025 is $41-$43 million.
- Anticipated net product revenue for FY 2025 is $192-$198 million.
- Anticipated royalty revenue for Q1 2025 is $1.5-$2.5 million.
- Anticipated royalty revenue for FY 2025 is $20-$24 million.
- Anticipated net income for FY 2025 is $23-$28 million.
Challenges Ahead
- Anticipated net income for Q1 2025 is $(2)-$0 million, indicating a potential loss.
- No license revenue is anticipated for Q1 2025 or FY 2025.
- Gross to Net Adjustment for Q1 2025 is projected at 22.5%-23.5%.
- Gross to Net Adjustment for FY 2025 is projected at 20.5%-21.5%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...